Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Porta

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
European Journal of Human Genetics : EJHG|November 5, 1998
A new candidate region for the positional cloning of the XLP geneA Bolino, L Yin, M Seri, et al.
European Review for Medical and Pharmacological Sciences|April 25, 2020
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experienceF Diurno, F G Numis, G Porta, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Nature Genetics|October 15, 1998
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding geneA J Coffey, R A Brooksbank, O Brandau, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
European Journal of Human Genetics : EJHG|November 5, 1998
A new candidate region for the positional cloning of the XLP geneA Bolino, L Yin, M Seri, et al.
European Review for Medical and Pharmacological Sciences|April 25, 2020
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experienceF Diurno, F G Numis, G Porta, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Nature Genetics|October 15, 1998
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding geneA J Coffey, R A Brooksbank, O Brandau, et al.
Pageof 8